Dose-reduced FCR first-line therapy in fit elderly CLL patients is safe, tolerable, and highly effective: first report of final statistical analysis from end of study and 12 month follow-up of ALLG CLL5 randomised dose de-escalation study

Stephen Mulligan, Paul Turner, Devinder Gill, Maya Latimer, William Renwick, Rosemary Harrup, Gavin Cull, Cecily Forsyth, Naomi Mackinlay, Leanne Berkahn, Phillip Campbell, David Simpson, Constantine Tam, Melanie Sulda, Giles Best, Mathias Bressel, Juliana Di Iulio, Bryone Kuss

Research output: Contribution to journal › Meeting Abstract › peer-review

Fingerprint

Dive into the research topics of 'Dose-reduced FCR first-line therapy in fit elderly CLL patients is safe, tolerable, and highly effective: first report of final statistical analysis from end of study and 12 month follow-up of ALLG CLL5 randomised dose de-escalation study'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science